Kiyoshi Ariizumi
Overview
Explore the profile of Kiyoshi Ariizumi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
944
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hannan R, Dohopolski M, Pop L, Mannala S, Watumull L, Mathews D, et al.
Biomedicines
. 2022 Jun;
10(6).
PMID: 35740441
(1) We hypothesized that adding concurrent stereotactic ablative radiotherapy (SAbR) would increase the time to progression in patients with metastatic castrate-resistant prostate cancer (mCRPCA) treated with sipuleucel-T. (2) Patients with...
2.
Ramani V, Chung J, Ariizumi K, Cruz Jr P
J Invest Dermatol
. 2021 Oct;
142(5):1372-1380.e5.
PMID: 34695414
Previously, we discovered antigen-presenting cells to express DC-HIL receptor and to secrete its soluble form (soluble DC-HIL [sDC-HIL]), both of which bind to syndecan-4 on T cells and endothelial cells...
3.
Chung J, Ramani V, Kobayashi M, Fattah F, Popat V, Zhang S, et al.
Clin Cancer Res
. 2019 Dec;
26(6):1449-1459.
PMID: 31822499
Purpose: Immune checkpoint inhibitors (ICI) benefit only a minority of treated patients with cancer. Identification of biomarkers distinguishing responders and nonresponders will improve management of patients with cancer. Because the...
4.
Brosseau J, Liao C, Wang Y, Ramani V, Vandergriff T, Lee M, et al.
Nat Commun
. 2018 Nov;
9(1):5014.
PMID: 30479396
Neurofibromatosis type 1 (NF1) is an autosomal genetic disorder. Patients with NF1 are associated with mono-allelic loss of the tumor suppressor gene NF1 in their germline, which predisposes them to...
5.
Florez-Pollack S, Tseng L, Kobayashi M, Hosler G, Ariizumi K, Chong B
J Invest Dermatol
. 2018 Oct;
139(2):478-481.
PMID: 30300609
No abstract available.
6.
Kobayashi M, Chung J, Beg M, Arriaga Y, Verma U, Courtney K, et al.
Clin Cancer Res
. 2018 Jul;
25(2):828-838.
PMID: 30049749
Purpose: Blocking the function of myeloid-derived suppressor cells (MDSC) is an attractive approach for cancer immunotherapy. Having shown DC-HIL/GPNMB to be the T-cell-inhibitory receptor mediating the suppressor function of MDSCs,...
7.
Ramani V, Teshima T, Tamura K, Chung J, Kobayashi M, Cruz Jr P, et al.
J Invest Dermatol
. 2018 Jun;
138(11):2443-2451.
PMID: 29857071
Soluble factors from the primary tumor induce recruitment of bone marrow-derived progenitors to form tumor-supportive microenvironments or pre-metastatic niches in distal organs before metastasis. How tumor-secreted factors condition the sites...
8.
Cao L, Chung J, Teshima T, Feigenbaum L, Cruz Jr P, Jacobe H, et al.
J Invest Dermatol
. 2016 May;
136(9):1801-1810.
PMID: 27236103
Psoriasis vulgaris is an inflammatory skin disease caused by hyperactivated T cells regulated by positive and negative mechanisms; although the former have been much studied, the latter have not. We...
9.
Chung J, Tamura K, Cruz Jr P, Ariizumi K
J Invest Dermatol
. 2014 Jun;
134(11):2784-2794.
PMID: 24936834
A major barrier to successful cancer immunotherapy is the tumor's ability to induce T-cell tolerance by exploiting host regulatory mechanisms. Having discovered the DC-HIL receptor, which inhibits T-cell responses by...
10.
Turrentine J, Chung J, Nezafati K, Tamura K, Harker-Murray A, Huth J, et al.
J Invest Dermatol
. 2014 Jun;
134(11):2839-2842.
PMID: 24933321
No abstract available.